17/05/24 (Agence Europe) – On Friday 17 May, the European Institute of Innovation and Technology (EIT) announced that Oxford-based Ochre Bio, which is developing a pipeline of RNA-based therapies for patients with liver disease, had signed a deal worth more than $1 billion with European medicine manufacturer Boehringer Ingelheim. As part of this agreement, the start-up, supported by the EIT ‘Health’ community, will study potential treatments aimed at exploiting the liver’s...